toxylact: a02bx10 zolomidine

The first professional lActological database in the word

Zolimidine (ATC A02BX10) is an imidazole derivative, formerly used as a gastroprotective agent for peptic ulcer disease and gastro‑oesophageal reflux, but it is now rarely employed and is considered unsuitable during breastfeeding because of its pharmacodynamic profile and potential neurotoxicity in breastfed infants.file+3

Drug identity and pharmacological class

  • INN: Zolimidine (also known as zoliridine).wikipedia+1
  • ATC code: A02BX10, subgroup “Other drugs for peptic ulcer and gastro‑oesophageal reflux disease (GORD)” within A02 “Drugs for acid related disorders”.kegg+2
  • Chemical class: Imidazole derivative, small molecule.ebi+1
  • Approximate molecular weight: about 272 Da (kiloDaltons).file+1

Zolimidine has been used as a gastroprotective drug in peptic ulcer disease and gastro‑oesophageal reflux, but its clinical role has largely been displaced by newer, more effective agents such as proton pump inhibitors. It exhibits gastric antisecretory and gastrokinetic activity; its antacid/antisecretory effect is attributed to a potassium‑competitive mechanism at the gastric acid secretory apparatus, with potency reported to be similar to that of esomeprazole.drugbank+2

Indications and regulatory status

  • Historical indications: Treatment of gastric and duodenal peptic ulcer disease and gastro‑oesophageal reflux disease.medpedia.framar+1
  • Therapeutic group: Other drugs for peptic ulcer and GORD (A02BX).wikipedia+1
  • Regulatory status: Not approved/registered in Bulgaria according to local reference; global use appears limited and historical.gsrs.ncats.nih+1

Because of the availability of safer and more effective alternatives for acid‑related disorders, zolimidine is seldom used in contemporary practice.drugbank+2

General toxicology

Experimental data indicate a wide therapeutic index, with an LD50 in animals of approximately 3700 mg/kg, suggesting relatively low acute systemic toxicity at therapeutic doses. Nonetheless, imidazole derivatives as a class can display a broad toxicological spectrum involving the central nervous system and the cardiovascular system, and some members have demonstrated mutagenic or teratogenic potential in preclinical models.pubmed.ncbi.nlm.nih+2

Zolimidine’s structure is related to other nitrogen‑containing imidazole derivatives, some of which act as agonists at the GABAA_AA​ receptor complex and exert pronounced sedative and anxiolytic effects, similar in qualitative terms to agents such as zolpidem, though via distinct binding domains. On this background, potential overdose or significant exposure may raise concerns for CNS depression, respiratory compromise, and cardiotoxic manifestations, particularly in vulnerable populations such as neonates and young infants.rjmp+3

Lactation pharmacology

Transfer into breast milk

Specific clinical pharmacokinetic data on zolimidine concentrations in human breast milk are lacking. However, based on its relatively low molecular weight (~272 Da), passage into human milk is expected to occur to at least some extent. In the absence of measured milk/plasma ratios or infant serum levels, risk assessment must rely on physicochemical properties, class effects, and theoretical considerations.ncbi.nlm.nih+3

Imidazole derivatives, especially those with GABAA_AA​ agonist activity, have the potential to cause CNS depression in breastfed infants, even at modest exposures, given immature hepatic metabolism and blood–brain barrier in early life. The possibility of additional toxicities (cardiotoxicity, mutagenicity/teratogenicity, or other class‑related adverse effects) further reinforces a cautious approach in the absence of direct lactation data.pubmed.ncbi.nlm.nih+2

Infant risk during breastfeeding

Considering the expected milk transfer and the pharmacodynamic profile described above, zolimidine is regarded as inappropriate during breastfeeding in the local toxicology‑lactology reference. The principal concerns include:file

  • Risk of infant CNS depression (sedation, hypotonia, poor feeding, respiratory depression) due to GABAA_AA​ agonist activity.rjmp+2
  • Potential cardiotoxic effects, particularly in neonates with limited cardiovascular reserve.pubmed.ncbi.nlm.nih+1
  • Theoretical long‑term risks associated with imidazole derivatives, including mutagenic or teratogenic potential, although specific data for zolimidine in human lactation are absent.rjmp+1

In the cited local classification, zolimidine is assigned to a toxic‑lactational risk Category IV – completely unsuitable for use during lactation. International lactation databases emphasize that many medications can be used safely during breastfeeding but that agents lacking data and with potentially serious pharmacodynamic effects should be avoided when safer alternatives exist. Zolimidine fits this latter profile.europeanjournalofmidwifery+3

Maternal therapy and alternatives

For breastfeeding women with peptic ulcer disease or GORD, current international practice favors medications with well‑characterized safety profiles in lactation, such as certain proton pump inhibitors or H2_22​‑receptor antagonists, which are generally considered compatible with breastfeeding when clinically indicated. Given the lack of lactation data for zolimidine, its imidazole nature, and the availability of safer options, replacement therapy with a better‑studied agent is advised instead of initiating or continuing zolimidine during breastfeeding.europeanjournalofmidwifery+3

If inadvertent exposure occurs (e.g., a single dose taken by a breastfeeding mother), close monitoring of the infant for signs of sedation, feeding difficulties, or respiratory compromise is prudent, and consultation with a clinical toxicologist or a specialized lactation pharmacology service is recommended.ncbi.nlm.nih+2

Pregnancy considerations

No FDA pregnancy category has been formally assigned to zolimidine in the available references. Data on use during pregnancy are very limited, and the imidazole class background, including reports of mutagenic or teratogenic effects in some structurally related compounds, suggests that zolimidine should be avoided in pregnancy whenever safer therapeutic alternatives are available. In women who are pregnant or planning pregnancy, acid‑related disorders should preferentially be treated with drugs with established reproductive safety profiles.drugbank+4

Summary of toxico‑lactological assessment

  • Zolimidine is an imidazole‑based gastroprotective drug (ATC A02BX10) with historical use in peptic ulcer and GORD.wikipedia+2
  • It has a wide therapeutic index in animal studies but belongs to a class associated with CNS and cardiotoxic effects and possible genotoxic/teratogenic risks.file+2
  • Although specific human lactation pharmacokinetic data are lacking, its low molecular weight and pharmacology indicate likely transfer into breast milk with potential for significant effects in the breastfed infant.ebi+2
  • A local toxicology‑lactology database therefore classifies zolimidine as completely unsuitable during lactation (Category IV) and recommends against its use in breastfeeding women, favoring safer alternatives for acid‑related disorders.ncbi.nlm.nih+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.